Arbutus Biopharma Corporation has announced that it has had three abstracts featuring imdusiran data and one abstract featuring ab-101 data accepted for poster presentations at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2025. The company's ab-101 abstract has been selected as a poster of distinction.
Key findings from the accepted abstracts include: Imdusiran therapy in patients with chronic hepatitis B virus (CHBV) was safe and well tolerated when administered at both 60 mg and 90 mg dose levels every 8 weeks for 4 – 6 doses and through up to 48 weeks of follow up after imdusiran dosing. In a limited dataset, the majority of subjects who achieved hepatitis B surface antigen (HBsAg) response during pegylated interferon alfa-2a (IFN) treatment with or following imdusiran dosing were genotype B or C, suggesting that imdusiran may enhance IFN responsiveness in CHBV patients with specific HBV genotypes. Imdusiran treatment is associated with increases in soluble immune biomarkers in both im-prove I and im-prove II studies. In subjects who lost HBsAg and had anti-HBs antibodies, a greater breadth and magnitude of immune biomarker increases were observed in im-prove I subjects compared to im-prove II. Oral doses of ab-101 up to 30 mg qd for 28 days were generally well tolerated in nucleos(t)ide analogue (NA)-suppressed CHBV patients. Preliminary interim pharmacodynamic data indicate dose-related increases in PD-L1 receptor occupancy, with 83% mean maximal receptor occupancy at the 30 mg dose.
The regular accepted abstracts are available to the public on the AASLD website and will be published in the October supplement of Hepatology. The poster presentations will be available on the AASLD website beginning November 7, 2025, at 8:00 am ET and will also be found on Arbutus’ website in the publications section.
Arbutus is currently developing imdusiran (ab-729) and an oral PD-L1 inhibitor (ab-101) for the treatment of CHBV infection, aiming to address the significant unmet medical need represented by CHBV infection. The company has also reported a total of eight patients with CHBV who have achieved a functional cure following treatment with imdusiran and NA therapy in combination with either IFN or low dose nivolumab plus an immunotherapeutic. Today the company's shares have moved -0.91% to a price of $4.34. Check out the company's full 8-K submission here.
